{"denomUnitsSelected":"Participants","description":"The observed rate will be calculated among patients with treatment failure who did not previously receive blinatumomab.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 12 weeks","title":"Proportion of Patients That Proceed to Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab (for Treatment Failure Patients Not Previously Receiving Blinatumomab)","type":"OTHER_PRE_SPECIFIED"}